Reddit posts revealed unreported drug interactions between cannabis products and immunosuppressants
Social media monitoring found Reddit users reporting dangerous interactions between consumer cannabis products and immunosuppressant medications, including some interactions not previously documented in clinical trials.
Quick Facts
What This Study Found
Searching 63.5 million Reddit posts, researchers identified 190 posts discussing both cannabis-derived products (CDPs) and immunosuppressants. Of these, 66 posts (35%) expressed concern about potential drug-drug interactions, and 4 posts (2%) reported actual adverse interactions. Two of the four matched the known CBD/tacrolimus interaction discovered in Epidiolex trials. Two others reported previously undocumented interactions: a CBD or THC/sirolimus interaction and a THC/tacrolimus interaction, both resulting in drug toxicity.
Key Numbers
63.5 million Reddit posts searched; 190 relevant posts identified; 66 (35%) expressed DDI concern; 4 (2%) reported actual DDI events; 2 novel interactions discovered: CBD/THC with sirolimus and THC with tacrolimus
How They Did This
Searched Reddit for subreddits related to cannabis-derived products or health, yielding 63,561,233 posts. Identified 190 posts discussing both immunosuppressants and CDPs. Two blinded investigators evaluated posts for DDI concerns and reported adverse events.
Why This Research Matters
Consumer cannabis products are unregulated and cannot be tested in clinical trials the way Epidiolex was. This study demonstrates that real-world drug interactions are occurring with consumer CBD and THC products and going unreported to formal pharmacovigilance systems, creating a hidden safety gap.
The Bigger Picture
As cannabis legalization expands while millions of Americans take immunosuppressants for organ transplants, autoimmune diseases, and cancer, the interaction risk grows. Traditional pharmacovigilance misses these events because consumer cannabis products exist outside the regulated pharmaceutical system.
What This Study Doesn't Tell Us
Social media data cannot verify clinical outcomes or confirm causation. Four reported DDI events is a very small number from which to draw conclusions. Reddit users may not accurately describe medications, doses, or outcomes. Cannot estimate the true incidence of these interactions.
Questions This Raises
- ?How many immunosuppressant patients use consumer cannabis products without informing their physicians?
- ?Should pharmacovigilance systems formally monitor social media for cannabis-drug interactions?
Trust & Context
- Key Stat:
- 35% of relevant Reddit posts expressed drug interaction concern
- Evidence Grade:
- Novel pharmacovigilance methodology identifies real safety signals, but social media data cannot verify clinical outcomes or establish interaction mechanisms.
- Study Age:
- 2025 publication
- Original Title:
- Pharmacovigilance in the Age of Legalized Cannabis: Using Social Media to Monitor Drug-Drug Interactions Between Immunosuppressants and Cannabis-Derived Products.
- Published In:
- Drug safety, 48(1), 99-105 (2025)
- Authors:
- Allen, Matthew R, Wightman, Gwenyth Portillo, Zhu, Zechariah, Poliak, Adam, Smith, Davey M, Dredze, Mark, Ayers, John W
- Database ID:
- RTHC-05912
Evidence Hierarchy
Watches what happens naturally without intervening.
What do these levels mean? →Frequently Asked Questions
What interactions were found?
Four Reddit users reported drug toxicity from combining cannabis products with immunosuppressants. Two involved the known CBD/tacrolimus interaction, while two were novel: a CBD or THC/sirolimus interaction and a THC/tacrolimus interaction.
Why are these interactions dangerous?
Immunosuppressants have narrow therapeutic windows, meaning small changes in blood levels can cause toxicity or organ rejection. Cannabis products can alter how these drugs are metabolized, pushing blood levels into dangerous ranges.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-05912APA
Allen, Matthew R; Wightman, Gwenyth Portillo; Zhu, Zechariah; Poliak, Adam; Smith, Davey M; Dredze, Mark; Ayers, John W. (2025). Pharmacovigilance in the Age of Legalized Cannabis: Using Social Media to Monitor Drug-Drug Interactions Between Immunosuppressants and Cannabis-Derived Products.. Drug safety, 48(1), 99-105. https://doi.org/10.1007/s40264-024-01481-x
MLA
Allen, Matthew R, et al. "Pharmacovigilance in the Age of Legalized Cannabis: Using Social Media to Monitor Drug-Drug Interactions Between Immunosuppressants and Cannabis-Derived Products.." Drug safety, 2025. https://doi.org/10.1007/s40264-024-01481-x
RethinkTHC
RethinkTHC Research Database. "Pharmacovigilance in the Age of Legalized Cannabis: Using So..." RTHC-05912. Retrieved from https://rethinkthc.com/research/allen-2025-pharmacovigilance-in-the-age
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.